Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Fig. 1

Timing of treatments. The time of T-VEC injection is set at 0. Types of treatment is indicated with different colors and durations of treatment is represented by the length of the line for each patient. II denotes suspension of treatment as a result of treatment-related adverse events. X denotes cessation of treatment due to progressive disease. AE, adverse events

Back to article page